{
    "organizations": [],
    "uuid": "73ad1c73fefb9c7823f0514570677bc00910a11c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-aveo-says-eusa-pharma-granted-posi/brief-aveo-says-eusa-pharma-granted-positive-nice-recommendation-for-fotivda-idUSFWN1Q210G",
    "ord_in_thread": 0,
    "title": "BRIEF-AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 26 PM / in 23 minutes BRIEF-AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Aveo Pharmaceuticals Inc: \n* AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA \n* AVEO PHARMACEUTICALS INC - ‍RECOMMENDATION TRIGGERS $2MLN MILESTONE PAYMENT FROM EUSA TO AVEO​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-12T14:26:00.000+02:00",
    "crawled": "2018-02-12T14:54:02.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "say",
        "eusa",
        "pharma",
        "granted",
        "positive",
        "nice",
        "recommendation",
        "fotivda",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "aveo",
        "pharmaceutical",
        "inc",
        "aveo",
        "announces",
        "eusa",
        "pharma",
        "granted",
        "positive",
        "nice",
        "recommendation",
        "tivozanib",
        "first",
        "line",
        "treatment",
        "advanced",
        "renal",
        "cell",
        "carcinoma",
        "aveo",
        "pharmaceutical",
        "inc",
        "trigger",
        "2mln",
        "milestone",
        "payment",
        "eusa",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}